Chronic hepatitis B occurs when the body cannot eliminate the hepatitis B virus following an acute infection. Having chronic (or lifelong) hepatitis B can increase a person’s risk of developing ...

FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...

Panel A shows the structure of HDV, which shares the hepatitis B surface antigen (HBsAg) envelope with hepatitis B virus. The virion contains a single-stranded, circular RNA genome of approximately ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...

This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2. NIAID-RML via AP A cancer patient with a ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an ...

Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

Mirum Pharmaceuticals (NasdaqGM:MIRM) reported positive primary endpoint results from its Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). The trial showed robust antiviral ...